Biogen Collaborates with GoodRx to Help Providers Start Patients on Vumerity

GoodRx announced a collaboration with Biogen that aims to improve the patient and healthcare provider (HCP) experience when initiating a new specialty therapy. HCPs who have decided to start patients with relapsing forms of multiple sclerosis (MS) on VUMERITY^® (diroximel fumarate) may now find the enrollment form and submit to the specialty hub through Provider Mode.

GoodRx also recently announced the launch of Provider Mode, a new experience that is built specifically for healthcare providers (HCPs) to help them find affordable solutions for the medications they prescribe.

Built by GoodRx’s own team of medical professionals along with external healthcare provider focus groups, Provider Mode offers customized tools designed to help HCPs and office staff support patients throughout their healthcare journey.

MS affects more than one million people in the United States. Starting patients on specialty therapies to treat conditions such as MS can be an arduous process for HCPs in terms of paperwork and for the patients themselves, who can at times wait up to three weeks for a prescription to be filled.

This new, digital enrollment in Provider Mode aims to expedite time to treatment initiation and significantly reduce the risk of documentation errors, which frequently occur when using traditional manual methods, including fax.

VUMERITY is an oral fumarate with a distinct chemical structure from TECFIDERA^® (dimethyl fumarate), approved in the U.S. for the treatment of relapsing forms of multiple sclerosis in adults, to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.

Once in the body, VUMERITY rapidly converts to monomethyl fumarate, the same active metabolite of dimethyl fumarate. VUMERITY is approved in more than 30 countries, and more than 20,000 patients have been treated with it, representing more than 15,000 patient-years of exposure across clinical trial use and patients prescribed VUMERITY.

Vumerity had global revenue of $137 million in the second quarter of 2022, an increase of 51% at actual currency and 52% at constant currency. Vumerity continued to grow in the U.S. and is now launched in 14 markets.

GoodRx’s technology delivers strong savings, trusted information and access to care to make healthcare affordable and convenient for all Americans. Since 2011, GoodRx has helped consumers save over $40 billion from pharmacy retail price and are one of the most downloaded medical apps over the past decade.

Takeaway: GoodRx’s Provider Mode is a new experience built specifically for HCPs to help them access solutions for the medications they prescribe